Skip to main navigation

For Patients

|

For Physicians

Header Links

Solutions
Investors
Meet the Team
News
Careers
Contact Us
For Patients
For Physicians

News Releases

Events and Presentations

Press Coverage
News Releases
Investor Calendar

Keyword Search

Year

05/25/22

Neuronetics to Present at the William Blair 42nd Annual Growth Stock Conference

05/17/22

New Peer-Reviewed Data Continue to Further Best Practices with NeuroStar® Advanced Therapy

05/12/22

Neuronetics Reports First Quarter 2022 Financial and Operating Results

05/11/22

Neuronetics and Transformations Care Network Announce Extended Commercial Partnership

05/11/22

Neuronetics TMS Leadership on Display at Clinical TMS Society Annual Meeting

05/11/22

Neuronetics Files Federal Lawsuit Against Brainsway for Misleading Psychiatrists and Patients

05/10/22

NeuroStar® Advanced Therapy for Mental Health Receives FDA Clearance for Treatment of Obsessive-Compulsive Disorder

05/06/22

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

05/03/22

NeuroStar Advanced Therapy for Mental Health Announces Partnership with Mental Health Advocate and Former Major League Baseball Player Drew Robinson

04/28/22

Neuronetics to Report First Quarter 2022 Financial and Operating Results and Host Conference Call

04/11/22

Greenbrook and Neuronetics Announce Strengthened Commercial Partnership to Build Awareness

03/08/22

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03/08/22

Neuronetics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results

03/03/22

NeuroStar® Advanced Therapy Launches New “Tap Into a New Possibility” Campaign for Depression Awareness

03/01/22

MT Cap for NeuroStar Advanced Therapy for Mental Health Now Available Nationwide

02/22/22

Neuronetics to Report Fourth Quarter and Fiscal Year 2021 Financial and Operating Results and Host Conference Call

02/22/22

Neuronetics Announces Amendment of Credit Facility with SLR Investment Corp.

01/10/22

NeuroStar Advanced Therapy for Mental Health Recognized as Top Neuromodulation Solution Provider in 2021

01/10/22

Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2021 Financial Results

Shareholder Tools

View printer-friendly version
RSS Feeds
E-mail Alerts
View contacts

Indication

NeuroStar TMS Therapy is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.

NeuroStar TMS Therapy is only available by prescription. A doctor can help decide if NeuroStar TMS Therapy is right for you.

Important Safety Information

The most common side effect is pain or discomfort at or near the treatment site. These events are transient; they occur during the TMS treatment course and do not occur for most patients after the first week of treatment. There is a rare risk of seizure associated with the use of NeuroStar TMS (<0.1% per patient).

TMS Therapy should not be used with patients who have non-removable conductive metal in or near the head. NeuroStar TMS Therapy has not been studied in patients who have not received prior antidepressant
Safety and Prescribing Information »

Our Commitment

Neuronetics is committed to compliance with state and federal laws regarding interaction with healthcare providers.
Commitment to Compliance »

Copyright @ 2022 Neuronetics Inc. All Rights Reserved.

Social Links

To find out more about NeuroStar TMS Therapy® or where treatment is available near you, please provide your contact information and a Neuronetics customer service representative will contact you. The information you provide to us is subject to the Neuronetics Privacy Policy.

General Contact Information

Customer Service Center: 1-877-600-7555